论文部分内容阅读
目的：对新生儿败血症患者静脉滴注去甲万古霉素进行药代动力学研究，探讨血药浓度与疗效、不良反应关系。方法：５例新生儿患者静滴去甲万古霉素１５ｍｇ·ｋｇ－１，进行药代动力学参数测定；观察临床疗效并进行不良反应监测。结果：峰浓度达（３４．８９±６．２３）ｍｇ·Ｌ－１，８～１２ｈ降至５ｍｇ·Ｌ－１以下，药物消除半衰期为（６．０８±１．２２）ｈ，表观分布容积为（０．４４±０．０８）Ｌ·ｋｇ－１，清除率为（０．０８９±０．０１４）Ｌ·ｋｇ－１·ｈ－１。治疗７～１４ｄ后，有明显疗效，未出现严重耳、肾毒性。结论：去甲万古霉素１５ｍｇ·ｋｇ－１静脉滴注后，能够维持有效药物浓度，用药间隔应为８～１２ｈ。该药物用于新生儿耐药葡萄球菌感染安全、有效。
Objective: Neonatal sepsis patients intravenous drip of norvancomycin pharmacokinetic study to explore the relationship between plasma concentration and efficacy, adverse reactions. Methods: Neonatal patients were intravenously drived with vancomycin 15 mg · kg-1, pharmacokinetic parameters were measured, the clinical efficacy and adverse reaction monitoring were observed. Results: The peak plasma concentration was (34.89 ± 6.23) mg · L-1,8 ~ 12h below 5 mg · L-1, the elimination half-life was (6.08 ± 1.22) h and the apparent distribution The volume was (0.44 ± 0.08) L · kg-1 and the clearance rate was (0.089 ± 0.014) L · kg-1 · h-1. After treatment 7 ~ 14d, there is obvious curative effect, does not appear serious ear, nephrotoxicity. CONCLUSION: After intravenous drip of norvancomycin 15 mg · kg-1, the effective drug concentration can be maintained. The interval should be 8-12 h. The drug is safe and effective for neonatal drug-resistant staphylococcal infection.